Predictive Oncology Inc. POAI NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score

29/100

1/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Predictive Oncology Inc. (POAI) has a negative trailing P/E of -0.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -267.47%, forward earnings yield 34.25%. PEG 0.02 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -0.4); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -267.47%).
Forward P/E 2.9 — analysts expect a return to profitability with estimated EPS of $1.20 for FY2026.
PEG Ratio 0.02 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Trailing Earnings Yield -267.47% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 34.25% as earnings recover.

Overall SharesGrow Score: 28/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

29/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✗

FUTURE

20/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

28/100

→ Income

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — POAI

Valuation Multiples

P/E (TTM)-0.4

Forward P/E2.9

PEG Ratio0.02

Forward PEG0.02

P/B Ratio1.83

P/S Ratio135.43

EV/EBITDA-0.1

Per Share Data

EPS (TTM)$-13.37

Forward EPS (Est.)$1.20

Book Value / Share$2.74

Revenue / Share$0.01

FCF / Share$-0.54

Yields & Fair Value

Earnings Yield-267.47%

Forward Earnings Yield34.25%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-18.2	-0.36	128.36	259.73	-
2017	-12.4	0.21	35.81	147.21	-
2018	-11.8	0.71	2,225.40	84.30	-
2019	-5.7	0.44	9.85	78.40	-
2020	-5.0	0.07	48.61	102.58	-
2021	-39.7	0.47	19.36	548.85	-
2022	-13.2	5.25	15.60	225.50	-
2023	-14.2	0.28	23.95	121.73	-
2024	-5.5	0.15	-331.08	41.31	-
2025	-0.5	0.00	2.61	994.73	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-462.28	$456.5K	$-6.53M	-1429.6%
2017	$-188.69	$654.84K	$-7.75M	-1183%
2018	$-157.40	$1.41M	$-10.09M	-714.5%
2019	$-137.20	$1.41M	$-27.56M	-1952.2%
2020	$-44.25	$1.25M	$-37.7M	-3010.7%
2021	$-7.20	$1.42M	$-19.66M	-1383.6%
2022	$-6.98	$1.51M	$-36.21M	-2405.1%
2023	$-3.48	$1.78M	$-13.98M	-785.6%
2024	$-2.32	$1.62M	$-12.2M	-751.4%
2025	$-13.37	$125.28K	$-233.1M	-186053.4%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$1.20	$1.20 – $1.20	$15.45M	$15.45M – $15.45M	1
2027	$4.05	$4.05 – $4.05	$23.97M	$23.97M – $23.97M	1
2028	$6.90	$6.90 – $6.90	$32.55M	$32.55M – $32.55M	1